Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
2020 · Journal of Thoracic Oncology · 399 citations
https://doi.org/10.1016/j.jtho.2020.01.017
D
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
197
Papers
4.3K
Citations
33
h-index
77
i10-index
Dawei Wu is an academic researcher from Chinese Academy of Medical Sciences & Peking Union Medical College. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Esophageal Cancer Research and Treatment & Health Systems, Economic Evaluations, Quality of Life. The author has an h-index of 33, co-authored 168 publications.
ORCID: 0000-0001-6096-8580Papers by this author
worksSafety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study
2018 · British Journal of Cancer · 156 citations
https://doi.org/10.1038/s41416-018-0100-3
Disruption of USP9X in macrophages promotes foam cell formation and atherosclerosis
2022 · Journal of Clinical Investigation · 119 citations
https://doi.org/10.1172/jci154217
The epidemiology, antifungal use and risk factors of death in elderly patients with candidemia: a multicentre retrospective study
2014 · BMC Infectious Diseases · 52 citations
https://doi.org/10.1186/s12879-014-0609-x
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
2022 · Journal of Hematology & Oncology · 23 citations
https://doi.org/10.1186/s13045-022-01227-1
Comparison of quantitative computed tomography analysis and single-indicator thermodilution to measure pulmonary edema in patients with acute respiratory distress syndrome
2014 · BioMedical Engineering OnLine · 16 citations
https://doi.org/10.1186/1475-925x-13-30
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat